Sonnet BioTherapeutics

Sonnet BioTherapeutics is a clinical-stage biotechnology company focused on developing innovative targeted biologic drugs for cancer treatment. Their proprietary FHAB™ (Fully Human Albumin Binding) technology platform enables the development of drugs with enhanced single- or bi-specific mechanisms. This platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB technology has demonstrated a 10-fold increase in half-life and a >30-fold increase in efficacy compared to recombinant interleukins without FHAB.

Sonnet's pipeline currently comprises five cytokine-derived therapeutic candidates. Their lead compound, SON-1010, is in Phase 1 development for the treatment of solid tumors. Other compounds, like SON-080, are in Phase 1b/2a development, while three additional compounds are undergoing preclinical studies. Sonnet is actively seeking partners and licensees to leverage the strength of their FHAB technology platform for drug development across the spectrum of human disease.

Sonnet BioTherapeutics is a clinical-stage biotechnology company dedicated to developing innovative, targeted biologic drugs to fight cancer. The company's proprietary FHAB (Fully Human Albumin Binding) technology enables the creation of enhanced single- or bi-specific drugs that "hitch-hike" on human serum albumin to deliver potent therapies directly to tumor sites. Sonnet's focus is on immune-oncology, with a pipeline of cytokine-derived therapeutic candidates designed to activate and sustain an anti-cancer immune response, aiming to improve the effectiveness of immunotherapy treatments.

Sonnet BioTherapeutics promotes a culture of innovation and expertise, driven by a team of industry leaders with extensive experience in drug discovery and development. The company emphasizes a collaborative and results-oriented environment, where scientific rigor and a deep understanding of immune biology are paramount. This is evident in their focus on their proprietary FHAB technology platform, which they believe holds immense potential for advancing the fight against cancer through targeted immune-oncology therapies.